Clinical trial
Fosamprenavir Expanded Access
NCT00240552 · ViiV Healthcare, Industry · Completed
Key facts
| NCT number | NCT00240552 |
|---|---|
| Title | Fosamprenavir Expanded Access |
| Official title | An Open-label Phase III Study to Provide Access to Fosamprenavir and to Assess the Long Term Safety and Tolerability of Fosamprenavir Containing Regimens in HIV Infected Patients With Limited Treatment Options |
| Lead sponsor | ViiV Healthcare, Industry |
| Collaborators | GlaxoSmithKline Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Infection, Human Immunodeficiency Virus |
| Intervention type | Drug |
| Interventions | fosamprenavir, Telzir® |
| Enrollment | 85 |
| Start date | Jul 1, 2003 |
| Completion | Aug 1, 2005 |
| First posted | Oct 18, 2005 |
| Last update posted | Sep 12, 2016 |
| Countries | Switzerland |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: